[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,742,285
  • Shares Outstanding, K 111,186
  • Annual Sales, $ 0 K
  • Annual Income, $ -144,740 K
  • EBIT $ -159 M
  • EBITDA $ -164 M
  • 60-Month Beta -0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.21

Options Overview Details

View History
  • Implied Volatility 73.06% (+9.41%)
  • Historical Volatility 58.50%
  • IV Percentile 28%
  • IV Rank 19.81%
  • IV High 196.61% on 02/12/26
  • IV Low 42.53% on 04/30/26
  • Expected Move (DTE 28) 1.06 (6.78%)
  • Put/Call Vol Ratio 5.55
  • Today's Volume 360
  • Volume Avg (30-Day) 274
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 12,695
  • Open Int (30-Day) 12,046
  • Expected Range 14.61 to 16.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 4
  • High Estimate $-0.33
  • Low Estimate $-0.41
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) +21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.44 +25.96%
on 05/19/26
16.20 -3.27%
on 06/18/26
+2.81 (+21.85%)
since 05/18/26
3-Month
12.44 +25.96%
on 05/19/26
18.60 -15.78%
on 04/17/26
+1.88 (+13.63%)
since 03/18/26
52-Week
4.80 +226.46%
on 06/23/25
18.60 -15.78%
on 04/17/26
+10.57 (+207.25%)
since 06/18/25

Most Recent Stories

More News
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking...

AMLX : 15.67 (+2.75%)
Amylyx Stock: Why the Full Pipeline Story Matters

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

AMLX : 15.67 (+2.75%)
MRK : 113.87 (-1.36%)
REGN : 609.94 (+0.33%)
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple...

AMLX : 15.67 (+2.75%)
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the...

AMLX : 15.67 (+2.75%)
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 ...

AMLX : 15.67 (+2.75%)
Amylyx's Pivot From Neurodegenerative to Obesity Meets Its First Revenue Deadline

Barchart Research What to Expect from AMLX Earnings AMLX Generated May 6, 2026 Current Price $16.06 EPS Estimate $$-0.34 Consensus Rating Strong Buy Average Move 4.73% Amylyx's Pivot From Neurodegenerative...

AMLX : 15.67 (+2.75%)
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being...

AMLX : 15.67 (+2.75%)
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

The Expanded Access Program allows eligible adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery access to avexitide, an investigational, first-in-class glucagon-like peptide-1...

AMLX : 15.67 (+2.75%)
Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2026 financial results on Thursday, May 7, 2026. Amylyx’s senior management team...

AMLX : 15.67 (+2.75%)
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

AMLX : 15.67 (+2.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 17.03
2nd Resistance Point 16.61
1st Resistance Point 16.14
Last Price 15.67
1st Support Level 15.26
2nd Support Level 14.84
3rd Support Level 14.37

See More

52-Week High 18.60
Last Price 15.67
Fibonacci 61.8% 13.33
Fibonacci 50% 11.70
Fibonacci 38.2% 10.07
52-Week Low 4.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.